Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← All stories
Federal PolicyJune 17, 2026

FDA Approves Third Over-the-Counter Naloxone Nasal Spray

The FDA approved Rextovy, a 4mg naloxone nasal spray, for over-the-counter sale in pharmacies, convenience stores, and online for emergency treatment of opioid overdose. This is the third OTC naloxone product approved by FDA. The approval expands consumer access to overdose reversal medication without a prescription. For Medicaid managed care organizations, this may affect pharmacy benefit management, member education strategies, and harm reduction program design, particularly for plans serving populations with substance use disorders.

Why it mattersIncreased OTC naloxone availability may shift dispensing patterns, require updates to formulary management and prior authorization protocols, and create new opportunities for MCO-led overdose prevention initiatives.

Behavioral Health · Pharmacy · Managed Care

Read the full article at thehill.com →
Share this briefing

You might also like

← All stories

Get the daily briefing.